Clinical Trials Directory

Trials / Terminated

TerminatedNCT00210002

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

Evaluation of Systematic Intravenous Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced.

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
55 (planned)
Sponsor
Institut Claudius Regaud · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the response rate obtained in an heterogeneous oncologic population treated by chemotherapy, and either by Darbepoetin alfa classic treatment or by association of Darbepoetin alfa -ferric saccharose systematic supplementation, administered concomitantly with chemotherapy.

Conditions

Interventions

TypeNameDescription
DRUGDarbepoetin alfa (Aranesp®)
DRUGFerric saccharose(Venofer®)

Timeline

Start date
2003-11-01
Completion
2006-04-01
First posted
2005-09-21
Last updated
2006-11-14

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00210002. Inclusion in this directory is not an endorsement.

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced (NCT00210002) · Clinical Trials Directory